Unspecified Childhood Solid Tumor, Protocol Specific
Conditions
Keywords
unspecified childhood solid tumor, protocol specific
Brief summary
RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving dactinomycin may help doctors learn how dactinomycin works in the body and how patients will respond to treatment. PURPOSE: This laboratory study is evaluating the pharmacokinetics of dactinomycin in young patients with cancer.
Detailed description
OBJECTIVES: * Determine the pharmacokinetics (PKs) of dactinomycin in pediatric patients with cancer. * Determine the degree of interpatient variation in the PKs of this drug. * Determine the influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs in these patients. * Correlate drug PKs with clinical response and toxicity observed in these patients, focusing particularly on the incidence of severe liver toxicity or veno-occlusive disease. * Correlate pharmacogenetic variability with clinical and PK data. OUTLINE: This is a multicenter study. Patients undergo blood collection for pharmacokinetic sampling of dactinomycin at baseline (prior to the initiation of dactinomycin) and periodically during course 1 of chemotherapy. An additional blood sample is obtained before or after treatment for the collection of peripheral blood lymphocytes. DNA from these cells is isolated and investigated for genetic variation in genes relevant to the pharmacology of dactinomycin. Plasma concentrations of dactinomycin are determined by liquid chromatography mass spectrometry analysis. Patients are followed for 2 years. PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Interventions
Sponsors
Children's Cancer and Leukaemia Group
Eligibility
Sex/Gender
ALL
Age
No minimum to 21 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of cancer * Currently being treated with dactinomycin on a clinical trial at a United Kingdom Children's Cancer Study Group center PATIENT CHARACTERISTICS: * Single- or double-lumen central venous catheter or portacath in place PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation of drug PKs with clinical response and toxicity, particularly the incidence of severe liver toxicity or veno-occlusive disease | — |
| Pharmacokinetics (PKs) of dactinomycin | — |
| Degree of interpatient variation of drug PKs | — |
| Influence of characteristics such as age, tumor type, and concurrent therapy on drug PKs | — |
Countries
Ireland, United Kingdom
Outcome results
None listed